UnitedHealth Group, the nation’s largest health insurer, kicks off the quarterly reporting season for its sector on Tuesday, presenting the earliest glimpse into how major players are navigating elevated medical and pharmaceutical expenses. In the third quarter of 2025, UnitedHealth reported revenues of $113.16 billion, a 12.2% increase year-over-year, while earnings per share reached $2.92, surpassing consensus estimates by $0.05. Management noted that medical cost trend pressures eased modestly to a 7.5% increase, down from 8.3% in the prior quarter, driven by lower inpatient utilization and price concessions on specialty drugs. Operating cash flow rose by 9%, and benefit expense as a percentage of revenue improved by 30 basis points. Investors will scrutinize whether the company’s Optum services division continues to deliver margin expansion, having achieved a 19.2% return on equity in the latest period.

Representative Julie Johnson of Texas disclosed the sale of between $1,001 and $15,000 in UnitedHealth Group shares on December 18, 2025, through her Chase Brokerage Account. This marks her first transaction in health insurance stock since taking office in January 2025. Although the position size represents a tiny fraction of her overall portfolio—approximately 0.05%—the timing coincides with growing congressional scrutiny on insurer pricing practices and reimbursement negotiations. Johnson’s financial filings also show simultaneous sales of similar value in a half-dozen other blue-chip healthcare and industrial names, underscoring a broad rebalancing strategy rather than a targeted divestment.